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Atrial fibrillation (AF) is the commonest cardiac arrhythmia observed in clinical practice 
currently affecting 1-2% of the general population 1. With an increasing lifespan its prevalence 
will also increase. Whilst technological advances have resulted in earlier and easier diagnosis of 
AF even outside of the hospital setting, the appropriate selection of patients for specific 
pharmacotherapy or electrophysiological ablation procedures has not seen similar improvement. 
For example, using the Kardia Band by AliveCor integrated with Apple’s smart watch can give 
accurate electrocardiograms for the wearer, enabling early detection of asymptomatic AF 2-4. This 
device has obtained regulatory approval in Europe and whilst this can allow us to detect AF 
reliably early on, it remains to be seen how such early diagnosis can improve prognosis.  
Having thus improved the timely diagnosis of AF this places significant pressure on its 
treatment to reach the same standards with regards to both symptomatic and prognostic therapies.  
In the past, anti-arrhythmic drugs represented the only means of maintaining sinus rhythm. 
However, given their side-effects, especially with long-term use, and limited efficacy, 
interventional approaches such as percutaneous catheter ablation have become increasingly 
important 5.  Over the last 30 years, atrial fibrillation ablation has continued to develop, with its 
frequency and success steadily increasing6, 7. However, its widespread adoption has been limited 
by the frequent need for repeated ablation procedures in order to maintain sinus rhythm. 
Myocardial fibrosis (or scarring) has been suggested to play a key role in the need for re-ablation 8, 
9 with patients who have increased atrial or ventricular scarring having poorer outcomes with 
ablation procedures. Characterization of myocardial tissue therefore both pre- and also potentially 
post-procedure is important as it could enable appropriate selection of patients who will be more 
likely to have a successful outcome from an ablation procedure. In this review we will discuss 
mechanistic pathophysiology of myocardial fibrosis in AF and how this could potentially help 




The bi-directional relationship between myocardial fibrosis and atrial fibrillation 
AF is thought to be secondary to underlying heart disease in 70% of patients 10. The 
extracellular matrix (ECM) is largely formed by myofibroblasts, which are flat spindle shaped 
cells that proliferate profoundly in pathological conditions 11, 12. Tight connections between these 
fibroblasts form a multidimensional network that acts as a sensor of dynamic change within the 
myocardium 12. Myofibroblasts exhibit different electrophysiological properties compared to 
surrounding cardiomyocytes. For example, they are non-excitable cells but can mediate current 
transfer between cardiomyocytes via gap junctions 12.  Increased collagen deposition in the ECM 
is important in the process of electrophysiological remodelling, leading to shortening of action 
potential durations, increased heterogeneity of conduction and repolarization, and spontaneous 
induction of phase 4 depolarization 10, 12. Therefore, fibroblasts may be directly linked with not 
only triggered but also re-entrant arrhythmogenesis 13. Myocardial diffuse fibrosis is identified as 
the excess deposition of extracellular matrix material, which mainly consists of the protein 
collagen, by myofibroblasts within the myocardial tissue. This would further alter the 
electrophysiological properties of the atrial myocardium, thereby increasing the propensity of AF 
development. Following on from myocardial diffuse interstitial fibrosis, myocyte necrosis ensues 
and the myocardium becomes scarred with a pathological and irreversible process of replacement 
fibrosis. Myocardial fibrosis is therefore a spectrum of disease with diffuse interstitial fibrosis on 
the one side progressing to focal replacement fibrosis on the other. Both have been linked to 
arrhythmogenesis and in this review the general term myocardial fibrosis will be used when 
referring to either of the patterns of fibrosis in patients with AF.   
It is not just that myocardial fibrosis can promote AF, but AF can itself potentially promote 
atrial fibrosis 14, 15 causing a “chicken and egg” situation as sometimes it is unclear which is the 
cause and which is the result. The very rapid atrial rate and associated tachycardia in AF may 
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induce electrical remodelling, which is an attempt to adapt to new pathophysiological conditions 
12. The ECM undergoes alterations as fibrotic tissue replaces atrial cardiomyocytes by the release 
of pro-fibrotic factors, such as transforming growth factor -β1 (TGF) 16, platelet derived growth 
factor 17 and connective tissue growth factor 18. Therefore, AF is not only a consequence, but also 
a cause of, fibrosis lending support to the commonly used medical aphorism “AF begets more 
AF”, likely secondary to myocardial fibrosis 19. Interestingly, permanent AF can downregulate 
angiotensin II type 1 receptors and upregulate angiotensin II 20. Increased levels of angiotensin II 
may activate nicotinamide adenine dinucleotide phosphate (NADPH) oxidases and increase the 
release of reactive oxygen species 21, in turn promoting fibrosis 22. Similar mechanisms could exist 
in myocardial fibrosis-mediated ventricular fibrillation (VF) but are not as well established as 
atrial fibrosis-mediated AF. Although both share common signal transduction pathways, there are 
significant chamber-specific differences. Thus, the increase in TGF- β1 levels is higher in the atria 
than in the ventricles in transgenic mice with TGF- β1 overexpression 23. Furthermore, atrial 
fibroblasts respond to greater extents to angiotensin II than ventricular fibroblasts 24.  It is 
therefore likely that fibrosis (with the exception perhaps of an acute myocardial infarction) is not 
localised but likely to affect both atria and ventricles. Therefore as atrial fibrosis can be more 
challenging to quantify many studies have used myocardial ventricular fibrosis as a surrogate 
marker 25.  
 
Quantification of fibrosis with imaging and relationship to ablation success 
Advances in cardiac imaging have enabled not only characterization but also quantification 
of cardiac fibrosis non-invasively 26. Echocardiography was the first investigation designed to 
screen for underlying cardiac pathologies that can influence the success or failure rates of ablation 
26. Some examples are left atrial dilatation, valvular heart disease or left ventricular systolic 
impairment 26. Cardiovascular magnetic resonance (CMR) has revolutionalized this field as it can 
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non-invasively provide myocardial tissue characterization which can provide further prognostic 
information in a plethora of cardiac conditions 27-29. CMR using late (delayed) gadolinium 
enhancement (LGE) can accurately quantify focal areas of atrial fibrotic tissue and scar burden. 
This is dependent on uptake of gadolinium by the cardiac tissue, and it is retained for longer 
periods in fibrotic cells compared to normal cells. Thus areas of damaged myocardium appear 
hyper-intense relative to the normal myocardium 30.  Indeed more fibrosis has been associated 
with increased recurrence following the ablation.  This further supports the use of CMR in the 
prediction of AF recurrence rates after ablation 31.  
Several studies have investigated the association between fibrosis assessed by CMR-LGE 
and ablation outcomes in the context of AF. The DECAAF study, a multicenter, prospective trial, 
revealed that atrial fibrosis estimated by CMR-LGE is independently associated with likelihood of 
recurrent arrhythmia after ablation 27. This study proposed a 4-stage classification of left atrial 
(LA) fibrosis:  Stage I (<10% of the LA wall), stage II (10-20%), stage III (20-30%) and stage IV 
(≥30%).  The AF post-ablation recurrence rates correlated with the classification stage of fibrosis, 
with recurrence rates of 15%, 33%, 46% and 51% respectively at 325 days indicating a more than 
a threefold increase in recurrence risk in the group with higher fibrosis burden than the group with 
lower fibrosis burden 27. A more recent study that followed up 50 patients post pulmonary vein 
isolation procedures demonstrated the patients who had AF recurrence had a mean 6.6% of atrial 
LGE scar compared to 3.5% in those who did not have a recurrence, further supporting that atrial 
scar is an independent factor for recurrence 32. Moreover, an additional study confirmed higher 
atrial arrhythmia recurrence risk with higher burden of fibrosis  ≥30% fibrosis (stage IV patients) 
on pre-ablation MRI scans over a one year follow-up period 33. This study concluded that LA wall 
fibrosis scores below 30% carry almost a third of the risk of recurrence when compared to patients 
with more than 30% atrial scarring on the pre-procedural CMR, and provides therefore a pathway 
towards identification of patients who are far more likely to benefit from catheter ablation 
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procedures. In summary, there is emerging evidence to support use of CMR-LGE to quantify atrial 
fibrosis both pre- and post-operatively for prognostication and although 30% of atrial fibrosis has 
significantly worse recurrence than lower values, it should be remembered that there is no 
threshold in terms of fibrosis and AF recurrence but likely a linear relationship. Therefore one 
could expect the best results when there is no atrial fibrosis- something potentially explaining why 
ablation in paroxysmal AF is more successful than permanent AF 34. 
The evaluation and risk stratification of fibrosis using LGE-MRI prior to ablation could be 
a personalized medical approach in the treatment of AF 35. It is noted that while a pulmonary vein 
isolation (PVI) ablation strategy is effective for patients with LA fibrosis in stages I and II, PVI 
fails to provide optimal outcomes for patients with stage III and IV fibrotic remodeling. While 
non-PV triggers, such as foci arising from atrial chambers or other thoracic arteries, can lead to 
recurrent atrial tachy-arrhythmias, most recurrences are due to pulmonary vein reconnection 36. 
Therefore, pre-procedure CMR can identify those patients who are unlikely to benefit from PVI 
but also those that could potentially require more extensive ablation during the first procedure in 
an attempt to minimize recurrence. Likewise, it is possible that patients with a very significant 
burden of fibrosis might be advised against ablation or quoted a very small percentage of success. 
CMR performed at 3 months post-ablation can be used to assess for the presence of continuous 
scar lesions and effective PVI 37.  Due to the poor results of PVI on patients with LA fibrosis in 
stages III and IV 9,  it is recommended to consider posterior and septal wall debulking (i.e. the 
surgical removal of tissue) or a completely different treatment approach due to the high risk of 
recurrence 9, 33.  
Whilst CMR-LGE is ideal for analyzing focal areas of cardiac replacement fibrosis, more 
recent techniques using T1 mapping are more commonly used to evaluate diffuse fibrosis 38. A 
recent study investigated the impact of diffuse atrial fibrosis detected by T1 mapping on the post-
AF ablation clinical outcome 39. It found a post-contrast atrial T1 time of >230ms was associated 
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with an 85% single procedure success rate after AF ablation 39. This technique of identifying 
diffuse interstitial fibrosis has been very welcomed in the imaging community as it has the 
potential to image “early” myocardial fibrosis. This form of early fibrosis could be potentially 
reversible and therefore scanning the patients following the ablation can allow us to see whether 
the diffuse fibrosis has stabilised, progressed or even regressed. Certainly if it has stabilised or 
regressed this would be a better situation, or if it has progressed we will know at least that the 
patients will be more at risk of a recurrence and ensure closer monitoring 26,30.    
 
Targeting fibrosis in ablation using electro-anatomical voltage mapping 
Patients with identified fibrosis undergoing catheter ablation have been associated with an 
increased likelihood of arrhythmia recurrence 40. Electro-anatomic voltage mapping (EAVM) can 
provide information on local voltage abnormalities to accurately identify myocardial fibrosis 41. It 
can characterize the underlying atrial substrate and identify areas injured by previous ablation 42. 
A number of studies have demonstrated accurate identification of ventricular fibrosis using 
specific voltage cut-off values, however the values for atrial fibrosis are less well defined 40. By 
using EAVM in combination with CMR, it was recently shown that areas of dense fibrosis have 
smaller voltages than those of patchy fibrosis (0.63mV vs. 0.86mV) 43.  These findings are 
supported by those of another study, which demonstrated an association between areas with 
increased fibrosis identified by CMR-LGE and lower voltages (0.7 mV) in the left atrium of AF 
patients 44.  Moreover, a voltage cut-off of 0.27 mV was suggested as a good value for delineating 
scars in AF with sensitivity of 90% and specificity of 83%) 41.  It should be noted that several 
factors can affect accurate voltage measurements, such as contact between the myocardium and 
the mapping catheter, the orientation of the catheter, underlying atrial rhythm, and the electrode 




Blood markers of fibrosis in predicting ablation success 
Recent research efforts have focused on elucidating the roles of inflammatory pathways in 
atrial fibrillation. As such, systemic inflammatory markers may provide utility in predicting AF 
ablation success 45. One promising candidate is metalloproteinase-2 (MMP-2), which has been 
shown to predict AF recurrence rates after ablation procedures 46-48.  A study involving 50 patients 
with symptomatic AF showed that baseline serum MMP-2 was significantly higher in patients 
with AF recurrence than in patients who remained in sinus rhythm over a 14-month post-ablation 
period 46. The ability of this marker to predict AF recurrence rates has been confirmed in two other 
studies 47, 48. Another promising marker is the amino terminal peptide of type III procollagen 
(PIIINP), which is generated during collagen type III biosynthesis 49. It is upregulated during 
fibrogenesis and scar formation 50. Higher PIIINP levels over the first six months after ablation 
predicted recurrent AF 51.  Other biomarkers, such as metallopeptidase inhibitor 2 (TIMP2), 
galectin-3 (Gal-3) and transforming growth factor beta (TGFβ) have also been examined for their 
ability to predict AF recurrence, but these failed to predict AF recurrent post-ablation in 
multivariate Cox regression analysis 47. The use of biomarkers in clinical practice is likely to 
increase significantly in the next few years, especially if they can associate with success of 
recurrence before or after the procedure.  
 
Conclusion 
With an ageing population and increasing prevalence and burden of AF, the role of AF 
ablation is likely to increase. However, it is possible that personalised/precision medicine will 
improve our selection of patients for this procedure and therefore tailor to the individual patients- 
by offering a simple procedure to those with low or no fibrosis, offering a more complex 
procedure to those with moderate fibrosis and even declining the procedure to those with very 
high burden of fibrosis who would be unlikely to benefit from it. Definite guidelines using the 
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presence of fibrosis will need to be developed and are likely to also include the use of biomarkers 
of fibrosis, as this would be simpler, cheaper and more reproducible than CMR which would also 
be well-received by the electrophysiological community12. Ultimately, a clinical score to predict 
outcome based on different modalities, for example CMR and blood biomarkers, will prove useful 
for this purpose 26, similar to the scoring systems that exist for  guiding selection of anticoagulants 
in AF 52 or primary prevention for atrial arrhythmia, ventricular arrhythmia or stroke in 
cardiomyopathy .  
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